My lack of understanding [Regulatives / Guidelines]

posted by GSTATS Homepage – India, 2010-05-29 07:28 (5867 d 19:20 ago) – Posting: # 5398
Views: 18,203

Hi Elmaestro,

❝ I am afraid I am not able to see the practical applicability of that; for any data point associated with ref. there will be two dose levels, or perhaps three if you're right this will only be the case if we assume Emin is the same for both test and ref. (reasonable, if you ask me) and equal to the effect at run-in. The latter lacks qualification and I would really be surprised if the FDA would allow that kind of assumption. It would not fit into my image of those gents.


Emin or E0 is same for both test and reference as it is a value obtained in run in period when dose level is zero and FDA has mentioned in there recommendation that "This modified model is based on assumption that both E0 and Emax are the same for the test and reference products".

GSTATS
http://www.gstatsolutions.com/Clinical%20Research.html

Let Noble Thoughts come from Every Side: RIG VEDA

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
155 visitors (0 registered, 155 guests [including 33 identified bots]).
Forum time: 02:49 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5